Cx43 reverses the resistance of A549 lung adenocarcinoma cells to cisplatin by inhibiting EMT

Oncology Reports

Volumn 31, Issue 6, 2014, Pages 2751-2758

  Yu, Meiling ^a   Zhang, Cuiling ^a   Li, Li ^a   Dong, Shuying ^a   Zhang, Naiju ^a   Tong, Xuhui ^a  

^a BENGBU MEDICAL COLLEGE   (China)

Author keywords

A549; Cisplatin; Cx43; Epithelial mesenchymal transition; Lung cancer

Indexed keywords

CISPLATIN; CONNEXIN 43; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; UVOMORULIN; VIMENTIN;

A549 CELL LINE; ARTICLE; CANCER CELL; CANCER CELL LINE; CANCER GROWTH; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EXPOSURE; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; ADENOCARCINOMA; BIOSYNTHESIS; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA; CELL LINE, TUMOR; CISPLATIN; CONNEXIN 43; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS;

EID: 84902201219     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3163     Document Type: Article

References (39)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
2. Ota S, Ishii G, Goto K, et al: Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer 64: 98-104, 2009.
3. Kajiyama H, Shibata K, Terauchi M, et al: Chemoresistance to paclitaxel induces epithelial mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol 31: 277-283, 2007.
4. Yang AD, Fan F, Camp ER, et al: Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 12: 4147-4153, 2006.
5. Hiscox S, Jiang WG, Obermeier K, et al: Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of β-catenin phosphorylation. Int J Cancer 118: 290-301, 2006. (Pubitemid 41779067)
6. Hiscox S, Morgan L, Barrow D, Dutkowskil C, Wakeling A and Nicholson RI: Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839). Clin Exp Metastasis 21: 201-212, 2004. (Pubitemid 39158497)
7. Chang CJ, Chao CH, Xia W, et al: p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol 13: 317-323, 2011.
8. Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890, 2009.
9. Voulgari A and Pintzas A: Epithelial-mesenchymal transition in cancer metastasis: mechanism, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 1796: 75-90, 2009.
10. Hugo H, Ackland ML, Blick T, et al: Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol 213: 374-383, 2007. (Pubitemid 47509716)
11. Min C, Eddy SF, Sherr DH and Sonenshein GE: NF-κB and epithelial to mesenchymal transition of cancer. J Cell Biochem 104: 733-744, 2008. (Pubitemid 351830825)
12. Proksch E, Brandner JM and Jensen JM: The skin: an indispensable barrier. Exp Dermatol 17: 1063-1072, 2008.
13. Laird DW: Life cycle of connexins in health and disease. J Biochem 394: 527-543, 2006.
14. Cronier L, Crespin S, Strale PO, Defamie N and Mesnil M: Gap junctions and cancer: new functions for an old story. Antioxid Redox Signal 11: 323-338, 2009.
15. Plante I, Stewart MK, Barr K, Allan AL and Laird DW: Cx43 suppresses mammary tumor metastasis to the lung in a Cx43 mutant mouse model of human disease. Oncogene 30: 1681-1692, 2011.
16. Ogawa K, Pitchakarn P, Suzuki S, et al: Silencing of connexin 43 suppresses invasion, migration and lung metastasis of rat hepatocellular carcinoma cells. Cancer Sci 103: 860-867, 2012.
17. Willecke K, Eiberger J, Degen J, et al: Structural and functional diversity of connexin genes in the mouse and human genome. Biol Chem 383: 725-737, 2002. (Pubitemid 34649891)
18. Okuma A, Kuraoka A, Iida H, Inai T, Wasano K and Shibata Y: Colocalization of connexin 43 and connexin 45 but absence of connexin 40 in granulosa cell gap junctions of rat ovary. J Reprod Fertil 107: 255-264, 1996.
19. Risley MS, Tan IP, Roy C and Saez JC: Cell-, age- and stage dependent distribution of connexin43 gap junctions in testes. J Cell Sci 103: 81-96, 1992.
20. de Oliveira KD, Tedardi MV, Cogliati B and Dagli ML: Higher incidence of lung adenocarcinomaa induced by DMBA in Cx43 heterozygous knockout mice. Biomed Res Int 2013: 618475, 2013. doi: 10.1155/2013/618475.
21. Zhao W, Han HB and Zhang ZQ: Suppression of lung cancer cell invasion and metastasis by Cx43 involves the secretion of follistatin-like 1 mediated via histone acetylation. Int J Biochem Cell Biol 43: 1459-1468, 2011.
22. Xu HT, Li QC, Zhang YX, et al: Cx43 recruits E-cadherin expression and inhibits the malignant behaviour of lung cancer cells. Folia Histochem Cytobiol 46: 315-321, 2008.
23. Zhang YX, Xu HT, Qi FJ and Wang EH: Expression of Cx43 in lung cancer and its correlation with E-cadherin. Zhonghua Bing Li Xue Za Zhi 35: 339-343, 2006 (In Chinese).
24. Chen Q, Qian B, Yang L and Jiang Z: The expression of Cx43 protein in non-small cell lung cancer tissues and its clinical significance. Zhongguo Fei Ai Za Zhi 6: 272-274, 2003 (In Chinese). (Pubitemid 37039644)
25. Cesen-Cummings K, Fernstrom MJ, Malkinson AM and Ruch RJ: Frequent reduction of GJIC and Cx43 expression in human and mouse lung carcinoma cells. Carcinogenesis 19: 61-67, 1998.
26. Lin Z, Zhang Z and Wang N: Inhibition of in vivo growth of lung carcinoma cells after transfetion with gap junction gene Cx43. Zhonghua Zhong Liu Za Zhi 19: 253-255, 1997 (In Chinese).
27. Du G, Yang Y, Zhang Y, et al: Thrombocytosis and immunohistochemical expression of connexin43 at diagnosis predict survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol 71: 893-904, 2013.
28. Zhang L, Sharma S, Hershman JM, Brent GA, Dubinett SM and Huang M: Iodide sensitizes genetically modified non-small cell lung cancer cells to ionizing radiation. Cancer Gene Ther 13: 74-81, 2006. (Pubitemid 41816351)
29. Yu ML, Zhang CL, Yuan DD, Tong XH and Tao L: Panax notoginseng saponins enhances the cytotoxicity of cisplatin via increasing gap junction intercellular communication. Biol Pharm Bull 35: 1230-1237, 2012.
30. Kim KS, Yao L, Lee YC, et al: Hyul-Tong-Ryung suppresses PMA-induced MMP-9 expression by inhibiting AP-1-mediated gene expression via ERK1/2 signaling pathway in MCF-7 human breast cancer cells. Immunopharmacol Immunotoxicol 32: 600-606, 2010.
31. Wang Z, Li Y, Kong D, et al: Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 69: 2400-2407, 2009.
32. Rho JK, Choi YJ, Lee JK, et al: Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer 63: 219-226, 2009.
33. Tan J, You Y, Xu T, et al: Par-4 downregulation confers cisplatin resistance in pancreatic cancercells via PI3K/Akt pathway-dependent EMT. Toxicol Lett 224: 7-15, 2013.
34. Kitamura K, Seike M, Okano T, et al: MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells. Mol Cancer Ther 13: 444-453, 2014.
35. Wu Q, Wang R, Yang Q, et al: Chemoresistance to gemcitabine in hepatoma cells induces epithelial-mesenchymal transition and involves activation of PDGF-D pathway. Oncotarget 4: 1999-2009, 2013.
36. Haslehurst AM, Koti M, Dharsee M, et al: EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer 12: 91, 2012. doi: 10.1186/1471-2407-12-91, 2012.
37. Sato H, Iwata H, Takano Y, et al: Enhanced effect of Cx43 on cisplatin-induced cytotoxicity in mesothelima cells. J Pharmacol Sci 110: 466-475, 2009.
38. Hong X, Wang Q, Yang Y, et al: Gap junctions propagate opposite effects in normal and tumor testicular cells in response to cisplatin. Cancer Lett 317: 165-171, 2012.
39. Huang RP, Hossain MZ, Huang R, Gano J, Fan Y and Boynton AL: Connexin 43 (cx43) enhances chemotherapy-induce apoptosis in human glioblastoma cells. Int J Cancer 92: 130-138, 2001. (Pubitemid 32187042)